Bill Allan – Chairman
Bill is an internationally- experienced medical devices executive who has held a number of general management and leadership positions with global medical device companies, including Smith & Nephew, Angiodynamics, Orthovita and Stryker.
He has a strong track record of building businesses and launching new products and has worked in Europe, Africa and North America.
Educated at the University of Edinburgh, University of Capetown and Insead Business School, Bill is a mentor at Cambridge University (Judge) Business School and a council member of ABHI (Association of British Healthcare Industries).
Anne Blackwood – Non-Executive Director
Dr Anne Blackwood is currently Chief Executive of Health Enterprise East, a leading NHS Innovation Hub and Technology Consultancy.
Anne has been actively involved in knowledge transfer and intellectual property management in the life sciences for over 15 years.
Since becoming Chief Executive at HEE, Anne has successfully transformed the organisation into a professional services company with a wide range of public and private sector clients.
Anne is also a Director of the Health Innovations Alliance which represents the body of NHS Innovation Hubs nationally.
Prior to joining HEE, Anne spent 4 years with Cambridge Enterprise, the Technology Transfer arm of the University of Cambridge. Anne holds a PhD in chemistry from Strathclyde University.
David Brooks – Chief Executive Officer
David is founder and CEO of Ablatus Therapeutics.
David has over 25 years’ experience in R&D and creating value from early-stage technologies, including drugs, devices and diagnostics.
Previously, David was responsible for clinical and business development at TwistDx, a subsidiary of Alere and business development, investor relations and product development at an AIM-listed biotechnology company. David has worked in regulatory affairs at GSK and as a postdoc was a PI on a project building transgenic models of colorectal neoplasia.
David holds a PhD from the University of Cambridge and an MBA from OUBS.
Heather Carre-Skinner – Acting Head of Regulatory
Following a BSc in Applied Microbiology and MSc in Biomedical Science from the University of Portsmouth, Heather gained her PhD from the Royal Veterinary College in molecular microbiology.
Heather spent her first postdoc position at the National Institute of Biological Standards and Control in the production of National and International Standards for biological assays. Working within this arena sparked Heather’s interests in Regulatory authorities and the role Quality Assurance plays within commercial organisations.
In 2010, Heather moved to Twist Dx Ltd, Cambridge as a Senior Scientist and Quality Assurance Engineer. She assisted in the implementation of medical device standard, ISO 13485 as well as focusing on transitioning research projects to a Quality and Regulatory framework, risk management and technical file production.
In August 2015 Heather moved to Congenica Ltd, Cambridge, a software company specialising in patient management with rare genetic disorders. Heather acted as Quality Assurance and Regulatory Affairs Manager and successfully implemented and managed quality and business systems ISO 13485:2016 and ISO 27001:2013/2017, as well as producing technical files for CE marking submission.
Professor Marcus Flather – Non-Executive Director
Marcus Flather graduated from the Royal Free Hospital School of Medicine, University of London in 1982 and trained in general medicine and cardiology in London and Oxford.
In 1993 he moved to McMaster University in Hamilton, Canada until 1996 when he took up the post of Director of the new Clinical Trials and Evaluation Unit (CTEU) at the Royal Brompton and Harefield Hospitals.
In September 2011 he took up the post of Professor of Medicine and Clinical Trials at the University of East Anglia and Director of Research at the Norfolk and Norwich University Hospitals NHS Foundation Trust in Norwich.
Marcus Flather is a Fellow of the Royal College of Physicians (UK) and holds a certificate of higher specialist training in Cardiology and General (Internal) Medicine in the UK (CCST). He has about 200 peer reviewed publications, is a recognised expert in clinical trials and has more than 20 years experience of collaborating with industry partners in drug and device development.
Jason Warren – Investment Associate of NVM
Jason, who will be working from NVM’s Reading office, spent his early career as a software engineer in the financial sector.
After completing the graduate scheme at Morgan Stanley, Jason joined the securitised products development team where he built data and analytic tools for strategists and traders.
Following this, he worked as a quantitative developer for a systematic hedge fund, acting as the lead developer on the rewrite of the trade generation system and working closely with the research team to implement trading algorithms.
Prior to this, Jason completed both an undergraduate and a Master’s degree in Mathematics and Computer Science at the University of Oxford, graduating with a First Class Honours and winning the Worcester College Society Award for Science Subjects.